Prospective drug utilization review definition

Prospective drug utilization review means that part of the drug utilization review program that occurs before the drug is dispensed and is designed to screen for potential drug therapy problems based on knowledge of the patient, the patient’s continued drug use and the drug use criteria and standards developed by the board.
Sample 1Sample 2Sample 3
Prospective drug utilization review or “pro-DUR" means a client-specific drug utilization review prior to dispensing;
Sample 1Sample 2Sample 3
Prospective drug utilization review means that part of the drug utilization review
Sample 1Sample 2Sample 3

Examples of Prospective drug utilization review in a sentence

  • Prospective drug utilization review shall include a review conducted by the pharmacist at the point-of- sale.

  • Prospective drug utilization review shall include a review conducted by the pharmacist at the point-of-sale.

  • Iowa Medicaid has implemented both of the required DUR types:♦ Prospective drug utilization review occurs when the pharmacist does the review of patient drug therapy at the point of sale.

  • Prospective drug utilization review shall include a review conducted by the pharmacist at the point of sale.

  • Prospective drug utilization review involves a review of drug therapy before each prescription is filled or delivered to a member and includes counseling of the member or their caregiver.

  • Prospective drug utilization review (PDUR) consists of interventions performed by a pharmacist prior to a drug being dispensed to a fee for service (FFS) Medicaid client.

  • Prospective drug utilization review (PDUR) consists of interventions performed by a pharmacist prior to a drug being dispensed to a Medicaid, Pharmaceutical Assistance to the Aged and Disabled (PAAD), Senior Gold, or AIDS Drug Distribution Program (ADDP) client who receives a drug benefit through these fee for service (FFS) programs.

  • Professional Practice Procedures 128§515 Prospective drug utilization review 128§517 Patient counseling 128§519 State of emergency 129§521 Prescription orders to administer medication 130§523 Collaborative drug therapy management 131§525 Cognitive services 136Chapter 7.

  • The Prospective drug utilization review process consists of interventions performed by a pharmacist prior to a drug being dispensed to Medicaid /NJ FamilyCare (NJFC), Work First New Jersey (WFNJ)/General Assistance (GA), Pharmaceutical Assistance to the Aged and Disabled (PAAD), New Jersey Senior Gold Prescription Discount Program (Senior Gold), Cystic Fibrosis and AIDS Drug Distribution Program (ADDP) beneficiaries who receive drug benefits through the FFS program.

  • Prospective drug utilization review (DUR) “involves reviewing each prescription for an individual patient before it is dispensed to identify drug-related problems such as drug-drug interactions or drug-disease contraindications, therapeutic duplication, or other potential adverse drug events” (Fulda et al.


More Definitions of Prospective drug utilization review

Prospective drug utilization review means the evaluation and approval of medication orders prior to administration of the first dose by a Washington state licensed pharmacist to:
Sample 1Sample 2
Prospective drug utilization review or “Prospective DUR” means a review of drug utilization that is performed before a prescribed medication is covered under a Plan.
Sample 1

Related to Prospective drug utilization review

  • Drug utilization review means an evaluation of a prescription drug order and patient records for

  • Utilization review means the prospective (prior to), concurrent (during) or retrospective (after) review of any service to determine whether such service was properly authorized, constitutes a medically necessary service for purposes of benefit payment, and is a covered healthcare service under this plan. WE, US, and OUR means Blue Cross & Blue Shield of Rhode Island. WE, US, or OUR will have the same meaning whether italicized or not. YOU and YOUR means the subscriber or member enrolled for coverage under this agreement. YOU and YOUR will have the same meaning whether italicized or not.

  • Utilization review organization means an entity that conducts utilization review, other than a health carrier performing a review for its own health benefit plans.

  • Utilization review plan or "plan" means a written procedure for performing review.

  • Diagnostic clinical procedures manual means a collection of written procedures that describes each method (and other instructions and precautions) by which the licensee performs diagnostic clinical procedures; where each diagnostic clinical procedure has been approved by the authorized user and includes the radiopharmaceutical, dosage, and route of administration.

  • Clinical evaluation means a systematic and planned process to continuously generate, collect, analyse and assess the clinical data pertaining to a device in order to verify the safety and performance, including clinical benefits, of the device when used as intended by the manufacturer;

  • Approved clinical trial means a phase I, phase II, phase III, or phase IV clinical trial that is conducted in relation to the prevention, detection, or treatment of cancer or other life-threatening disease or Condition and is described in any of the following:

  • Clinical review criteria means the written screening procedures, decision abstracts, clinical protocols, and practice guidelines used by a health carrier to determine the necessity and appropriateness of health care services.

  • Participating Clinical Laboratory means a Clinical Laboratory which has a written agreement with the Claim Administrator or another Blue Cross and/or Blue Shield Plan to provide services to you at the time services are rendered.

  • Non-Participating Certified Clinical Nurse Specialist means a Certified Clinical Nurse Specialist who does not have a written agreement with the Claim Administrator or another Blue Cross and/or Blue Shield Plan to provide services to you at the time services are rendered.

  • Independent educational evaluation means an evaluation conducted by a qualified examiner who is not employed by the public agency responsible for the education of the child in question.

  • Designated chemical dependency specialist means a person

  • Non-Participating Clinical Laboratory means a Clinical Laboratory which does not have a written agreement with the Claim Administrator or another Blue Cross and/or Blue Shield Plan provide services to you at the time services are rendered.

  • Phase III Clinical Study means a trial involving administration of a Compound to sufficient numbers of human patients with the goal of establishing that the Compound is safe and efficacious for its intended use, to define warnings, precautions and adverse reactions that are associated with the drug or label expansion of such Compound, and to be considered as a pivotal study for submission of an NDA.

  • Pivotal Clinical Trial means a pivotal human clinical trial of a Licensed Product with a defined dose or a set of defined doses of such Licensed Product designed to ascertain efficacy and safety of such Licensed Product for the purpose of enabling the preparation and submission of an MAA to the competent Regulatory Authorities in a country of the Territory, as further defined in 21 C.F.R. § 312.21(c) for the U.S., as amended from time to time, or the corresponding foreign regulations.

  • Core Curriculum Content Standards means the New Jersey Student Learning Standards.

  • Participating Certified Clinical Nurse Specialist means a Certified Clinical Nurse Specialist who has a written agreement with the Claim Administrator or another Blue Cross and/or Blue Shield Plan to provide services to you at the time services are rendered.

  • Phase 4 Clinical Trial means a Clinical Study in any country which is conducted after Regulatory Approval of a product has been obtained from an appropriate Regulatory Authority, consisting of trials conducted voluntarily for enhancing marketing or scientific knowledge of an approved indication and trials conducted due to request or requirement of a Regulatory Authority.

  • Phase III Clinical Trials means a Clinical Trial for the Product on sufficient numbers of patients to generate safety and efficacy data to support Regulatory Approval in the proposed therapeutic indication, conducted in accordance with current good clinical practices and in accordance with a protocol that has been reviewed by the FDA and reflects any comments or concerns raised by the same.

  • Adverse Drug Experience means any of: an “adverse drug experience,” a “life-threatening adverse drug experience,” a “serious adverse drug experience,” or an “unexpected adverse drug experience,” as those terms are defined at either 21 C.F.R. § 312.32 or 21 C.F.R. § 314.80.

  • Collaborative drug therapy management means participation by an authorized pharmacist and a physician in the management of drug therapy pursuant to a written community practice protocol or a written hospital practice protocol.

  • Analytical x-ray system means a group of components utilizing x-rays to determine the elemental composition or to examine the microstructure of materials.

  • Clinical laboratory means a facility for the microbiological, serological, chemical, hematological, radiobioassay, cytological, immunohematological, pathological, or other examination of materials derived from the human body for the purpose of providing information for the diagnosis, prevention, or treatment of a disease or assessment of a medical condition.

  • Phase I Clinical Study means, as to a particular Licensed Product, an initial clinical study in humans with the purpose of assessing the Licensed Product’s safety, tolerability, toxicity, pharmacokinetics or other pharmacological properties.

  • Phase 2 Clinical Trial means a human clinical trial of a product in any country that would satisfy the requirements of 21 C.F.R. 312.21(b) and is intended to explore a variety of doses, dose response, and duration of effect, and to generate initial evidence of clinical safety and activity in a target patient population, or a similar clinical study prescribed by the relevant Regulatory Authorities in a country other than the United States.

  • Phase 1 Clinical Trial means a Clinical Trial of a Product on sufficient numbers of normal volunteers and/or patients that is designed to establish that such Product is safe for its intended use and to support its continued testing in Phase 2 Clinical Trials. For purposes of this Agreement, ‘initiation’ of a Phase 1 Clinical Trial for a Product means the first dosing of such Product in a human subject in a Phase 1 Clinical Trial.